Thyrocare Technologies Ratios

Thyrocare Technologies Ltd Ratios

The Thyrocare Technologies Ltd Ratios page provides a complete fundamental analysis of Thyrocare Technologies Ltd using key valuation, profitability, and financial strength metrics. Investors tracking Thyrocare Technologies Ltd Ratios closely monitor D/E, EV, EV/EBITDA, P/B, P/CF, P/E, P/S, and ROE% to evaluate the company's financial performance and valuation trends over time.

Thyrocare Technologies Ltd (NSE: THYROCARE, BSE: 539871) is currently trading at ₹351.35, with a market capitalization of ₹56.17B. As a major player in the Health services sector and Medical/Nursing services industry, Thyrocare Technologies Ltd remains a key stock for fundamental analysis using Thyrocare Technologies Ltd Ratios.

Thyrocare Technologies Ltd Ratios: Valuation Overview

Price to Earnings Ratio (P/E)

The Thyrocare Technologies Ltd P/E ratio currently stands at 39.48, making it one of the most tracked metrics in Thyrocare Technologies Ltd Ratios.

Historically, the Thyrocare Technologies Ltd P/E ratio has shown strong fluctuations:

• 2024: 39.48
• 2023: 44.39
• 2022: 35.32
• 2021: 23.27
• 2020: 42.26

The decline in Thyrocare Technologies Ltd P/E ratio suggests improving earnings relative to stock price.

Price to Book Ratio (P/B)

The Thyrocare Technologies Ltd P/B ratio reflects how the market values the company's net assets. Current P/B ratio is 6.59.

Historical P/B trend:

• 2024: 6.59
• 2023: 5.95
• 2022: 4.26
• 2021: 7.77

Thyrocare Technologies Ltd is trading at a premium to its book value, indicating strong market confidence.

Price to Sales Ratio (P/S)

The Thyrocare Technologies Ltd P/S ratio currently stands at 5.26, an important part of Thyrocare Technologies Ltd Ratios for revenue valuation.

Historical P/S ratio:

• 2024: 5.26
• 2023: 5.49
• 2022: 4.32
• 2021: 6.96

A stable or declining Thyrocare Technologies Ltd P/S ratio indicates cautious market sentiment.

Thyrocare Technologies Ltd Price to Cash Flow Ratio (P/CF)

The Thyrocare Technologies Ltd Price to Cash Flow Ratio is a key valuation metric that shows how much investors pay for each unit of cash flow. Current P/CF ratio is 18.73.

Historical Thyrocare Technologies Ltd Price to Cash Flow Ratio:

• 2024: 18.73
• 2023: 19.11
• 2022: 17.44
• 2021: 36.68
• 2020: 41.13

The declining Thyrocare Technologies Ltd Price to Cash Flow Ratio suggests improving cash flow strength.

Thyrocare Technologies Ltd Enterprise Value Ratios

Enterprise Value (EV)

The Thyrocare Technologies Ltd EV currently stands at ₹34.46B, representing the total company valuation including debt.

Historical EV trend:

• 2024: 34.46B
• 2023: 30.08B
• 2022: 21.51B
• 2021: 39.81B

Thyrocare Technologies Ltd enterprise value shows long-term growth, reflecting expansion and market confidence.

EV/EBITDA Ratio

The Thyrocare Technologies Ltd EV/EBITDA ratio is currently 17.80, a key metric in Thyrocare Technologies Ltd Ratios to assess valuation relative to earnings.

Historical EV/EBITDA:

• 2024: 17.80
• 2023: 21.05
• 2022: 17.17
• 2021: 16.71

Stable Thyrocare Technologies Ltd EV/EBITDA indicates balanced valuation.

Thyrocare Technologies Ltd Financial Strength Ratios

Debt to Equity Ratio (D/E)

The Thyrocare Technologies Ltd D/E ratio is currently 0.05, reflecting leverage and financial stability.

Historical D/E:

• 2024: 0.05
• 2023: 0.08
• 2022: 0.04
• 2021: 0.04

Thyrocare Technologies Ltd maintains a strong balance sheet with low debt levels.

Return on Equity (ROE %)

The Thyrocare Technologies Ltd ROE currently stands at 17.05%, showing profitability and capital efficiency.

Historical ROE:

• 2024: 17.05
• 2023: 13.34
• 2022: 12.16
• 2021: 36.93

Thyrocare Technologies Ltd maintains stable profitability levels.

Thyrocare Technologies Ltd Ratios Analysis Summary

The Thyrocare Technologies Ltd Ratios page provides a comprehensive view of the company's valuation and financial performance. Key metrics such as P/E, P/B, P/S, P/CF, EV, EV/EBITDA, D/E, and ROE help investors understand whether Thyrocare Technologies Ltd stock is undervalued, fairly valued, or overvalued.

Tracking Thyrocare Technologies Ltd Ratios regularly helps investors make informed decisions based on valuation trends, financial stability, and long-term growth potential.